Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05480449 · ClinicalTrials.gov registry record · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
A Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) and B Lineage Lymphoblastic Lymphoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT05480449: Recruiting Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) and B Lineage Lymphoblastic Lymphoma, sponsored by Stephan Grupp MD PhD.
NCT05480449 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) and B Lineage Lymphoblastic Lymphoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 89 participants, below the 118-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05480449, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) and B Lineage Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
Primary Outcome
The safety of the administering Humanized Cd19-Directed Chimeric Antigen Receptor T-Cells (huCART9) will be measured by the monitoring the frequency and severity of adverse events in patients with advanced or refractory CD19+ hematologic malignancies, including those previously treated with cell therapy.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-09-20 |
| Est. Completion | 2029-09-20 |
| Phase | Phase 1 |
What NCT05480449 shows while recruiting
NCT05480449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 118-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with B-cell Acute Lymphoblastic Leukemia (B-ALL) appearing as the primary indexed condition, and to 1 intervention - of which Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19) is the first listed.
NCT05480449 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05480449 about?
NCT05480449 is a clinical study titled "Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)". This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
What is the current status of trial NCT05480449?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2022-09-20. Estimated completion is 2029-09-20.
What conditions does trial NCT05480449 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT05480449?
The interventions under investigation include: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05480449?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05480449 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
RECRUITING · Phase 1
-
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RECRUITING · Phase 1
-
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RECRUITING
-
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
RECRUITING · NA
-
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
- NCT07015983 · 89 participants · Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI